First OTC Oral Contraceptive Has Advisory Panel’s Unanimous Support Despite FDA’s Data Concerns
Executive Summary
FDA officials again made clear concerns about “improbable dosing” data in HRA’s sNDA for 0.075-mg norgestrel tablet branded Opill before advisory panel voted at close of a two-day meeting conducted 60 years after first Rx oral contraceptive approved in US.
You may also be interested in...
Biden Calls For Expanding Access To Reproductive Health Care, Including OTC Oral Contraceptives
President’s “Executive Order on Strengthening Access to Affordable, High-Quality Contraception and Family Planning Services” is third on reproductive health care access since Supreme Court’s Dobbs decision allowing states to regulate access to abortion services.
When History Has Its Eyes On You: Opill Vote Puts US FDA In Tough Spot
A unanimous US FDA advisory committee vote in favor of a landmark decision to make oral contraceptives available without a prescription should be history in the making. But the desire to make history – rather than address FDA’s significant concerns with the actual application for Perrigo’s Opill – seems to have carried the day.
When History Has Its Eyes On You: Opill Vote Puts US FDA In Tough Spot
A unanimous US FDA advisory committee vote in favor of a landmark decision to make oral contraceptives available without a prescription should be history in the making. But the desire to make history – rather than address FDA’s significant concerns with the actual application for Perrigo’s Opill – seems to have carried the day.